A Safety and efficacy study of febuxostat, a non-purine-selective inhibitor of xanthine oxidase, for prevention of tumor lysis syndrome in patients with hematological malignancies.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2017
At a glance
- Drugs Febuxostat (Primary)
- Indications Haematological malignancies; Leukaemia; Lymphoma; Tumour lysis syndrome
- Focus Registrational; Therapeutic Use
- 28 Nov 2015 New trial record